Nostrum Laboratories, Inc.

  1. December 03, 2024

    Nostrum Says Nearly 30 Potential Buyers Have Signed NDAs

    Drugmaker Nostrum Laboratories told a New Jersey bankruptcy judge Tuesday that close to 30 parties are weighing bids for the company's assets, with the debtor planning to choose a stalking horse bidder in the coming weeks.

  2. November 25, 2024

    Nostrum Wants Automatic Ch. 11 Stay Extended To CEO

    Drugmaker Nostrum Laboratories asked a New Jersey bankruptcy judge to extend its Chapter 11 automatic stay to its CEO and its parent company, Nostrum Pharmaceuticals LLC, both of which are nondebtors.

  3. November 01, 2024

    Under The Radar: Bankruptcy News You May Have Missed

    Rudy Giuliani was recently accused of ignoring subpoenas as two former election workers tried to collect on a $148 million defamation judgment, Steward Health Care creditors have opposed the formation of a tort claimants committee and Chinese exile Miles Guo's $26.5 million New Jersey mansion can be sold in Chapter 11.

  4. October 15, 2024

    Nostrum Says Ch. 11 Trustee Unnecessary

    New Jersey drugmaker Nostrum Laboratories has filed an opposition to Citizens Bank's motion to appoint a Chapter 11 trustee, arguing it was filed too early and is unneeded because Nostrum plans to sell its assets and pay Citizens in full. 

  5. October 07, 2024

    FTX Wins Plan Approval, Diamond Sports Drops MLB Deals

    FTX will start repaying customers using up to $16.5 billion in assets that the fallen cryptocurrency company has recovered since filing for bankruptcy in November 2022, after a Delaware bankruptcy judge blessed FTX's reorganization plan at a hearing Monday. 

  6. October 01, 2024

    Nostrum Labs Hits Ch. 11 A Year After Medicaid Settlement

    Nostrum Laboratories, a New Jersey drugmaker that paid millions to settle allegations that it underpaid Medicaid drug rebates for its bladder infection drug after it hiked the price more than 400%, filed for Chapter 11 protection with nearly $68.3 million in debt.